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Summary
Background and purpose: CYP2C19*2 loss-of-function allele in Caucasians may be associated
with wide interindividual variability in platelet response to clopidogrel, and the incidence of
gene mutation varies with racial differences, especially between Asians and Caucasians. The
aim was to examine the impact of CYP2C19 genotype on the residual platelet reactivity in
Japanese patients with coronary heart disease (CHD) during antiplatelet therapy.
Methods and results: We measured the CYP2C19 genotype and platelet aggregation in 201
patients with stable CHD. Moreover, we examined the relation of CYP2C19 polymorphism
to cardiovascular events in 98 patients treated with stent implantation. The distribution of
CYP2C19 genotype was 37%, 33%, 11%, 11%, 7%, and 1% in CYP2C19*1/*1, *1/*2, *1/*3, *2/*2,
*2/*3, and *3/*3, respectively. Residual platelet reactivity was lower in patients during dual
antiplatelet therapy (DAT) than in those with aspirin (3975± 1569 aggregation unitsminute
(AUmin) vs 5850± 938AUmin, p < 0.05). In the DAT group, the platelet reactivity decreased
∗ Corresponding author. Tel.: +81 96 373 5175; fax: +81 96 362 3256.
E-mail address: shokimot@kumamoto-u.ac.jp (S. Hokimoto).
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signiﬁcantly in the wild-type homozygotes (CYP2C19*1/*1), subsequently in the *2, or *3 heterozy-
gotes (*1/*2, *1/*3), and was not well inhibited in the *2, and/or *3 homozygotes (*2/*2, *2/*3,
*3/*3; 3194± 1570AUmin, 4148± 1400AUmin, and 5088± 1080AUmin, respectively). However,
when the duration of DAT was used to divide subjects into 2 groups, <7 days, and >7 days, patients
carrying the variant allele showed signiﬁcantly decreased platelet reactivities at >7 days com-
pared with those at <7 days. Moreover, the incidence of cardiovascular events was higher in
patients carrying at least one variant allele than in wild-type homozygotes.
Conclusions: CYP2C19 polymorphism may be associated with high residual platelet reactivity and
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induced by 20mol/L adenosine diphosphate (ADP; Chrono-
Log, Tokyo, Japan) was measured using a light transmission
aggregometer (MCM HEMA TRACER 313; PAM12C, LMS Inc.,the occurrence of cardiovasc
© 2011 Japanese College of C
Introduction
Dual antiplatelet therapy with aspirin plus clopidogrel
is currently recommended for the prevention of adverse
cardiovascular events in coronary heart disease (CHD)
patients treated with stent implantation [1,2]. Despite
dual antiplatelet therapy, however, some patients do not
achieve an adequate antiplatelet effect from clopidogrel
and a substantial number of subsequent ischemic events,
such as stent thrombosis, cardiovascular death, nonfa-
tal myocardial infarction, and stroke, still occur [3,4].
This may be partially because of wide interindividual
variability in the antiplatelet effect of clopidogrel. The
mechanisms leading to a poor response to clopidogrel have
not yet been fully elucidated and are most likely mul-
tifactorial. Besides some different clinical factors, such
as age, renal failure, obesity, diabetes, high plasma ﬁb-
rinogen, and lack of adherence [5—7], cytochrome P450
(CYP) polymorphisms are reported to be associated with
non- or hypo-responsiveness to clopidogrel [8,9]. In Western
countries, it has been demonstrated that patients carry-
ing at least one CYP2C19*2 loss-of-function allele exhibit
increased residual platelet aggregation and are at high risk
of adverse cardiovascular events despite clopidogrel admin-
istration [10,11]. On the other hand, besides CYP2C19*2,
a CYP2C19*3 variant allele has been reported in Asia,
which generates the null-activity enzyme protein [12,13].
The relation between CYP2C19 polymorphism, including
CYP2C19*3 as well as CYP2C19*2 allele, and the antiplatelet
efﬁcacy of clopidogrel is unknown in Japanese patients
with CHD. To address this issue, we examined the distri-
bution of CYP2C19 genotypes and platelet aggregation, and
assessed the impact of CYP2C19 polymorphism on response
to clopidogrel and clinical outcomes after stent implanta-
tion.
Methods
Study population
The study population consisted of 201 consecutive patients
who underwent cardiac catheterization upon diagnosis
with stable CHD. Patients receiving anticoagulants, or
antiplatelet agents other than clopidogrel or aspirin, were
excluded. The subjects were divided into 2 groups, (1)
dual antiplatelet therapy (DAT) group (n = 123), 100mg/day
aspirin plus 75mg/day clopidogrel as a maintenance dose
after 300mg of clopidogrel loading; and (2) aspirin group
(n = 78), aspirin at 100mg/day alone.
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The study protocol was in agreement with the guide-
ines of the ethical committee of the institution and written
nformed consent was obtained from each patient or the
amily of the subject.
enotyping
enomic DNA was extracted from whole blood using the
NA Extractor WB kit (Wako Pure Chemical Industries, Ltd.,
saka, Japan) using a modiﬁed protocol from Richards et al.
14]. Polymerase chain reaction restriction fragment length
olymorphisms for CYP2C19*2 (681G>A) and CYP2C19*3
636G>A) were performed as described previously [13,15].
YP2C19*2 and *3 are considered to account for >99% of
lleles generating the null-activity enzyme protein in the
apanese population [13]. Thus, CYP2C19 genotypes were
lassiﬁed into three phenotypes: (1) extensive metabolizer
EM) carrying normal function alleles (CYP2C19*1/*1); (2)
ntermediate metabolizer (IM) carrying one loss-of-function
llele (*1/*2, *1/*3); and (3) poor metabolizer (PM) carrying
wo loss-of-function alleles (*2/*2, *2/*3, *3/*3).
easurement of platelet aggregation
atients in the DAT group received a loading dose of clopi-
ogrel of 300mg, followed by a 75mg daily maintenance
ose. Platelet function test was performed at least 24 h
fter clopidogrel loading in the DAT group, and at least
days after aspirin at 100mg/day as a maintenance dose
n the aspirin alone group. In the DAT group, the time of
esting from the clopidogrel loading was in 10 patients at
4 h, 40 at 36 h, 10 at 48 h, 9 at 60 h, 50 at 168 h, and 4
t 216 h, respectively. In short, platelet aggregation test
as done in 69 patients at <7 days and 54 patients at >7
ays. Platelet aggregation was measured as below. Whole
amples of blood were obtained using a glass tube contain-
ng a solution of 0.38% sodium citrate. Platelet-rich plasma
as prepared by centrifugation at 900 rpm at room temper-
ture for 15min and then, to separate platelet-poor plasma,
entrifugation was also carried out at 3000 rpm at room
emperature for 10min. Aggregation in platelet-rich plasmaapan), where the degree of light transmission of platelet-
ich plasma was deﬁned as 0% of the aggregation rate, and
he cognitive platelet-poor plasma as 100%. Test time was
0min. On treatment platelet reactivity was deﬁned as the
rea under the platelet aggregation curve, which was used
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Table 1A Patient characteristics.
DAT Asp p-Value
Number 123 78
Male 81(66%) 53(68%) ns
Age (years) 68.6± 10.0 68.7± 9.8 ns
BMI (kg/m2) 24.0± 3.3 24.1± 3.7 ns
Diabetes 60(49%) 30(38%) ns
Hypertension 96(78%) 55(71%) ns
Dyslipidemia 75(61%) 44(56%) ns
Current smoker 20(16%) 14(18%) ns
Fibrinogen (mg/dl) 356.5± 104.5 341.8± 80.1 ns
Ejection fraction (%) 58.1± 9.9 61.2± 8.3 ns
eGFR (ml/min 1.73m2) 64.9± 16.2 68.2± 13.2 ns
8(10%) ns
53(67%) ns
eGFR, estimated glomerular ﬁltration rate; PPI, proton pump inhibitor.
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ity showed a lower value in the DAT group than in
the aspirin group as expected (3975± 1569AUmin vs
5850± 938AUmin, p < 0.05). However, values of platelet
reactivity in the DAT group varied widely and these results
indicate a wide variability in individual response to clopido-
grel.
CYP2C19 genotype and phenotype
The distribution of CYP2C19 genotype was 37%, 33%, 11%,
11%, 7%, and 1% in *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and
*3/*3, respectively (Fig. 2). Patients were divided into 3 phe-
notypes of CYP2C19 polymorphism: (1) EM; (2) IM; and (3)
8000
AU*min p<0.05
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7000
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5000
2000
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0
1000
AspDAT
78123n
Figure 1 Comparison of on-treatment platelet reactivity
according to antiplatelet therapy. Platelet aggregation (AUmin)
induced by 20mol/L adenosine diphosphate was measured
using a light transmission aggregometer. On-treatment platelet
reactivity showed a lower value in the DAT group than in thePPI use 32(26%)
Statin use 105(85%)
DAT, dual antiplatelet therapy; Asp, aspirin; BMI, body mass index;
o express the aggregation response over the measured time
aggregation unitsminute; AUmin).
linical outcomes
f the 123 patients receiving DAT scheduled for percuta-
eous coronary intervention (PCI), 98 underwent PCI due
o severe coronary stenosis. Thus, the clinical outcomes of
8 patients treated with coronary stent implantation were
valuated except for 25 subjects. The patients were fol-
owed up every month at the outpatient department for
ne year or at end point. The end point was cardiovascular
eath, nonfatal myocardial infarction, or ischemic stroke.
tatistical analysis
ontinuous variables are expressed as means± SD. Categor-
cal variables are expressed as frequencies and percentages.
tatistical analysis was carried out exclusively by inde-
endent statistician. The comparison between groups was
nalyzed using Pearson’s Chi-square test for categorical
ariables and Kruskal—Wallis or Mann—Whitney U test for
ontinuous variables. A p-value <0.05 was regarded as sig-
iﬁcant. The StatView 5.0 software (SAS Institute, Cary, NC,
SA) was used for all statistical analyses.
esults
atient characteristics
linical characteristics of each group (DAT and aspirin alone)
re shown in Table 1A. Antiplatelet therapy was DAT in 123
ases (61%) and aspirin in 78 (39%). There were no signif-
cant differences in baseline characteristics between DAT
nd aspirin groups.n-treatment platelet reactivity in all subjects
ig. 1 shows a comparison of platelet reactivity in the
AT and aspirin groups. On-treatment platelet reactiv-
aspirin group as expected (3975± 1569 vs 5850± 938AUmin,
p < 0.05). On-treatment platelet reactivities were compared
between two groups with Mann—Whitney U test. Asp, aspirin;
AU, aggregation units; DAT, dual antiplatelet therapy (clopido-
grel plus aspirin).
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Figure 2 Distribution of CYP2C19 genotype (right) and phenotype (left) in patients with stable coronary heart disease. EM,
extensive metabolizer, patients carrying normal function alleles (CYP2C19*1/*1); IM, intermediate metabolizer, patients carrying one
loss-of-function allele (CYP2C19*1/*2, *1/*3); PM, poor metabolizer, patients carrying two loss-of-function alleles (CYP2C19*2/*2,
*2/*3, *3/*3).
Table 1B Patient characteristics according to CYP2C19 phenotype in dual antiplatelet therapy group.
EM IM PM p-Value
Number 47 51 25
Male 31 (66%) 36 (73%) 14 (56%) ns
Age (years) 66.8± 10.8 68.6± 9.3 72.0± 9.1 ns
BMI (kg/m2) 24.9± 3.2 23.5± 3.3 23.5± 3.4 ns
Diabetes 21 (45%) 26 (53%) 13 (52%) ns
Hypertension 34 (72%) 42 (82%) 20 (80%) ns
Dyslipidemia 29 (61%) 30 (59%) 16 (64%) ns
Current smoker 8 (17%) 9 (18%) 6 (24%) ns
Previous MI 10 (21%) 10 (20%) 4 (16%) ns
Fibrinogen (mg/dl) 368.3± 121.8 345.0± 97.2 356.0± 84.5 ns
Ejection fraction (%) 58.1± 10.4 59.3± 9.9 58.9± 11.9 ns
eGFR (ml/min 1.73m2) 63.9± 17.3 64.2± 18.2 64.9± 16.1 ns
PPI use 9 (19%) 15 (29%) 8 (32%) ns
Statin use 38 (81%)
EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor me
estimated glomerular ﬁltration rate; PPI, proton pump inhibitor.
PM. The distribution of CYP2C19 phenotype was 37%, 44%,
and 19% in EM, IM, and PM, respectively (Fig. 2). Table 1B
lists the clinical characteristics according to CYP2C19 geno-
type in the DAT group. There were no signiﬁcant differences
in patient characteristics among the 3 phenotypes. As shown
in Table 2, the proportions of CYP2C19 variant alleles in
patients on DAT scheduled for PCI were 59%, 31%, and 10% in
CYP2C19*1 (wild type), *2, and *3, respectively, and the sim-
ilar distribution of CYP2C19 genotypes was seen compared
with that of all CHD patients. Fig. 3 shows a comparison
of on-clopidogrel platelet reactivity according to CYP2C19
genotypes in the DAT group. On-treatment platelet reactiv-
ity was signiﬁcantly lower in the EM group than the values in
Table 2 Ratio of CYP2C19*2, or *3 variant alleles in 123
patients taking dual antiplatelet therapy.
CYP2C19 Allele *1 *2 *3 Total
Number 145 76 25 246
Ratio 58.9% 30.9% 10.2% 100%
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a45 (88%) 22 (88%) ns
tabolizer; BMI, body mass index; MI, myocardial infarction; eGFR,
he IM and PM groups (EM, IM, and PM; 3194± 1570AUmin,
148± 1400AUmin, and 5088± 1080AUmin, respectively).
he average time of testing from the clopidogrel loading
as 94± 70 h, 88± 69 h, and 105± 71 h, in EM, IM, and PM,
espectively, and there was no difference in the measuring
ime of each group according to CYP2C19 genotypes.
n-treatment platelet reactivity according to time
etween clopidogrel loading and platelet function
est among EM, IM, and PM groups
s shown in Fig. 4, on-treatment platelet reactivity levels
t <7 days decreased compared with the values at >7 days in
he PM and IM groups. There were no differences in patient
haracteristics, such as age, sex, body mass index, diabetes,
ypertension, smoking, plasma ﬁbrinogen content, left ven-
ricular ejection fraction, estimated glomerular ﬁltration
ate, proton pump inhibitor use, and statin use, between the
wo groups. However, the ratio of dyslipidemia was higher in
7 days after clopidogrel loading than in <7 days. There was
great difference among EM, IM, and PM at <7 days; how-
198 K. Yamamoto et al.
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Figure 3 Comparison of the on-treatment platelet reactiv-
ity according to CYP2C19 genotype in patients during dual
antiplatelet therapy. On-clopidogrel platelet reactivity was sig-
niﬁcantly reduced in the EM group compared with those in the IM
and PM groups. EM, 3194± 1570AUmin; IM, 4184± 1400AUmin;
PM, 5088± 1080AUmin, at <7 days, and >7 days, respectively.
Platelet aggregation values between groups were compared
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Table 3A Cardiovascular events in patients with or without
variant alleles of CYP2C19*2, or *3.
CYP2C19*2, or *3 allele
Non-carriers
(n = 36)
Carriers
(n = 62)
End point 0 5
Cardiovascular death 0 1
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pith Mann—Whitney U test. AU, aggregation units; EM, exten-
ive metabolizer; IM, intermediate metabolizer; PM, poor
etabolizer.
ver, the huge gap was reduced at 7 days (EM, 3186± 1595,
007± 1541; IM, 4655± 1380, 3490± 1392; PM, 5663± 1385,
674± 824; at <7 days, and >7 days, respectively). There was
o signiﬁcant difference in on-clopidogrel platelet reactiv-
ty at >7 days between the EM and IM groups, however, the
alue of platelet reactivity in the PM group was signiﬁcantly
igher than those in the EM and IM groups. There were no
c
a
a
t
AU*min p<0.05
6000
7000
8000
p<0.05
4000
5000
1000
2000
3000
PMIMEM
0
(*1/*2, *1/*3) (*2/*2, *2/*3, *3/*3)(CYP2C19 *1/*1)
< 7 days
n=12n=32n=25
igure 4 On-treatment platelet reactivity according to time be
xtensive, intermediate, and poor metabolizer groups. EM, 3186±
663± 1385, and 4674± 824; at <7 days, and >7 days, respectively.
oor metabolizer. Data are shown as mean± SD. Statistical analysisMyocardial infarction 0 2
Stroke 0 2
igniﬁcant differences in the time from clopidogrel loading
o measuring among the EM, IM, and PM groups in the sub-
roups of < or >7 days (<7 days, 33± 12 h, 32± 13 h, and
0± 15 h in EM, IM, and PM; >7 days, 170± 10 h, 170± 10 h,
nd 176± 18 h in EM, IM, and PM, respectively).
ardiovascular events and CYP2C19 variant alleles
linical outcomes in patients undergoing PCI were as below:
ardiovascular death, 1 patient; nonfatal myocardial infarc-
ion, 2; ischemic stroke, 2 (Table 3A). All of these patients
ere carrying at least one variant allele of CYP2C19; details
f genotype were in three patients with CYP2C19*1/*2, one
atient with *1/*3, and one with *2/*2 alleles, and the peri-
ds from PCI to cardiovascular events were 1, 10, 21, 74, and
40 days (Table 3B). Kaplan—Meier analysis based on with
nd without variant allele of CYP2C19*2, or *3 showed a ten-
ency of increased risk of cardiovascular events in patients
arrying at least one of the CYP2C19 loss-of-function variant
lleles as compared with those carrying wild-type alleles,
lthough the case number and rate of events were too small
o be signiﬁcant (Fig. 5).
ns
p<0.05
PMIMEM
(*1/*2, *1/*3) (*2/*2, *2/*3, *3/*3)(CYP2C19 *1/*1)
7 days
n=13n=19n=22
tween clopidogrel loading and platelet function test among
1595AUmin, 3007± 1541; IM, 4655± 1380, 3490± 1392; PM,
EM, extensive metabolizer; IM, intermediate metabolizer; PM,
was performed with Mann—Whitney U test.
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Table 3B Details of cardiovascular events.
Day(s) Genotype Event
1 *1/*2 Stroke
10 *1/*2 Stroke
21 *1/*2 Myocardial infarction
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I74 *2/*2 Cardiovascular death
340 *1/*3 Myocardial infarction
Discussion
In this study, we measured ADP-induced platelet aggrega-
tion in patients with CHD during antiplatelet therapy, and
deﬁned the value of the area under the aggregation curve as
one of the platelet functional values. We used on-treatment
platelet reactivity directly, not inhibition of platelet aggre-
gation calculated as the percentage decrease in the relative
maximal platelet aggregation from the baseline. Observa-
tions of clopidogrel response that rely on baseline platelet
reactivity have recently been appreciated to be less reli-
able predictors of ischemic risk than posttreatment platelet
reactivity [16—18]. Moreover, the value of the area under
the aggregation curve (AUmin) is more sensitive and precise
than that of maximal platelet aggregation calculated from
a percentage of inhibition. Thus, we used the value of the
area under the aggregation curve as on-treatment platelet
reactivity during antiplatelet therapy. Although the impact
of CYP2C19 polymorphism on the antiplatelet efﬁcacy of
clopidogrel in Japanese patients scheduled for coronary
stent implantation has been reported [19], we enrolled
a substantial number of consecutive patients undergoing
cardiac catheterization for stable CHD and measured on-
treatment platelet reactivity at different sampling times
from clopidogrel loading to determine the effects accord-
ing to CYP2C19 genotype. Moreover, CYP2C19 genotype was
prone to be associated with the occurrence of major adverse
cardiovascular events after stent implantation. As such, we
consider this an important manuscript reporting the rela-
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Figure 5 Cumulative event rate of cardiovascular death,
nonfatal myocardial infarction, and stroke. There were cardio-
vascular events in 5 patients carrying at least one CYP2C19
variant alleles (Carrier), while none in patients carrying the
wild-type, normal-function alleles (Non-carrier).
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ion of CYP2C19 genomic variation to on-treatment platelet
eactivity and to clinical outcomes in Japanese patients tak-
ng DAT.
Recent studies have suggested that a wide interindivid-
al variability of response to clopidogrel is associated with
dverse cardiovascular events [16,20]. Different clinical fac-
ors and gene polymorphisms are considered to inﬂuence a
ersistent high platelet reactivity despite DAT with clopi-
ogrel and aspirin [5]. Not only CYP2C19*2 but also *3
oss-of-function alleles were found in Japanese patients in
ontrast to Caucasians, and the ratio of PMs that have two
oss-of-function alleles was 19%. The PM ratio is 2—3% in
estern countries, so these results indicate a huge gap in the
istribution of CYP2C19 polymorphism between Japanese
nd Caucasians. The ratio of patients exhibiting a high
n-treatment platelet reactivity was increased owing to a
igh frequency of CYP2C19*2 and *3 variant alleles in the
resent study, however, the incidence of adverse cardiovas-
ular events was low. Cardiovascular events including stent
hrombosis are generally reported to be lower in Japan than
n Western countries [21—23]. In spite of the high rate of PM
n Japanese patients, the reason for the low risk of clinical
utcomes remains unknown. Several studies in other coun-
ries have demonstrated that patients carrying at least one
on-functional allele of CYP2C19*2 show an increased on-
reatment platelet reactivity despite conventional DAT, and
hat it may be associated with an increased risk of adverse
ardiovascular events following coronary stent placement
8,9,11]. Moreover, the risk of early but not late stent throm-
osis is reported to increase in patients presenting with high
esidual platelet reactivity after stenting [24]. In this study,
n-clopidogrel platelet reactivity was most decreased in the
M group compared with those in the IM and PM groups.
owever, when classiﬁed by time between clopidogrel load-
ng and platelet function test, patients in both the PM and
M groups exhibited reduced on-clopidogrel platelet reac-
ivity at >7 days compared with that at <7 days. Moreover,
here was no signiﬁcant difference in on-treatment platelet
eactivity at >7 days between the EM and IM groups; how-
ver, the value of platelet reactivity even at >7 days in the
M group was signiﬁcantly higher than in the EM and IM
roups. The ratio of dyslipidemia was higher in >7 days after
lopidogrel loading than in <7 days. Elevated plasma ﬁbrino-
en in the presence of diabetes and increased body mass
ndex are reported to be associated with higher platelet
ggregation in patients with CHD [5], thus we do not think
hat dyslipidemia may affect the platelet aggregation in
his study. These results suggest that on-treatment platelet
eactivity according to CYP2C19 genotype depends on the
ime between clopidogrel loading and platelet function test
n Japanese CHD patients with variant alleles of not only
YP2C19*2 but also CYP2C19*3.
In the present study, we evaluated the clinical outcomes
n patients undergoing coronary stent implantation on DAT.
he occurrence of cardiovascular events was detected in
nly patients carrying CYP2C19 variant alleles, and the peri-
ds from PCI to cardiovascular events were 1, 10, 21, 74,
nd 340 days. We do not have the data on residual platelet
eactivity at the time of cardiovascular events, and the
elation of the residual platelet reactivity on clopidogrel
o clinical events is unknown. Although we speculate that
he underlying mechanisms of cardiovascular events may not
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ccount for the reduced antiplatelet effect of clopidogrel
lone, sample number and cardiovascular event rate were
oo small in this study, thus, we cannot examine the possibil-
ty of speculation. Further studies using larger samples are
eeded to examine whether CYP2C19 genomic variations are
elated to an increased risk of clinical cardiovascular events
n Japanese patients as well as Caucasians.
imitations
n the present study, values of platelet reactivity are not cal-
ulated from the values of changes between before and after
he administration of clopidogrel; therefore, we do not know
f the underlying platelet hyperreactivity per se accounts
or a higher on-clopidogrel platelet reactivity. We did not
easure plasma concentrations of the active metabolite
f clopidogrel, thus, we cannot provide direct evidence of
educed antiplatelet efﬁcacy of clopidogrel in patients car-
ying at least one CYP2C19*2 or *3 variant allele. In addition,
e cannot exclude the effect of other drug metabolism
nzymes, such as CYP1A2, 2B6, 3A, and 2C9, on clopi-
ogrel response, besides CYP2C19. In this study, CYP2C19
enomic variations were not associated with an increased
isk of cardiovascular events in carriers compared with non-
arriers, however, the small sample size might have affected
he power to detect such inﬂuence. Thus, further study is
eeded in the future.
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